Basem M Mishriky

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 10

Top Topics

Atrial Fibrillation

Systematic Review

Cardiovascular Events

Top Venues

Diabetes, obesity & metabolism

Diabetes/metabolism research and reviews

Postgraduate medicine

Journal of clinical pharmacology

This page only lists publications with an associated author ORCID identifier.

Publications

Basem M Mishriky, Doyle M Cummings, Yuanyuan Fu, Jacqueline R Halladay, Schuyler Jones, Andrea D Boan, Sara Jones, Shivajirao P Patil, James R Powell, Alyssa Adams, William Irish
Comparative analysis of hospitalization risk for incident heart failure in non-Hispanic Black versus non-Hispanic White individuals with type 2 diabetes on empagliflozin (Empa-AA): Insights from real-world data. Diabetes, obesity & metabolism 26 (5) (2024)
Basem M Mishriky, Doyle M Cummings, Yuanyuan Fu, Jacqueline R Halladay, Schuyler Jones, Andrea D Boan, Sara Jones, Shivajirao P Patil, James R Powell, Alyssa Adams, William Irish
Comparative analysis of hospitalization risk for incident heart failure in non-Hispanic Black versus non-Hispanic White individuals with type 2 diabetes on empagliflozin (Empa-AA): Insights from real-world data. Diabetes, obesity & metabolism (2024)
Basem M Mishriky, Doyle M Cummings, Yuanyuan Fu, Jacqueline R Halladay, Schuyler Jones, Andrea D Boan, Sara Jones, Shivajirao P Patil, James R Powell, Alyssa Adams, William Irish
Comparative analysis of hospitalization risk for incident heart failure in non-Hispanic Black versus non-Hispanic White individuals with type 2 diabetes on empagliflozin (Empa-AA): Insights from real-world data. Diabetes, obesity & metabolism 26 (5) (2024)
Basem M Mishriky, Doyle M Cummings, James R Powell
A meta-analysis of randomized controlled trials evaluating sodium-glucose co-transporter 2 inhibitors and incidental atrial fibrillation-Is there a true benefit? Diabetes/metabolism research and reviews (2023)
Zahra Hamedi, Basem M Mishriky, Victor Okunrintemi, James R Powell, Doyle M Cummings
GLP-1 RA and atrial fibrillation in the cardiovascular outcome trials. Diabetes/metabolism research and reviews 37 (5) (2021)
Jarrod L Uhrig, Stephanie O Page, Basem M Mishriky, Shivajirao P Patil, James R Powell, Kerry Sewell, Muna R Mian, Doyle M Cummings
Should Baseline Hemoglobin A1c or Dose of SGLT-2i Guide Treatment With SGLT-2i Versus DPP-4i in People With Type 2 Diabetes? A Meta-Analysis and Systematic Review. Journal of clinical pharmacology 60 (8) (2020)
Victor Okunrintemi, Basem M Mishriky, James R Powell, Doyle M Cummings
Sodium-glucose co-transporter-2 inhibitors and atrial fibrillation in the cardiovascular and renal outcome trials. Diabetes, obesity & metabolism 23 (1) (2020)
Basem M Mishriky, James R Powell, Jennifer A Wittwer, Jennifer X Chu, Kerry A Sewell, Qiang Wu, Doyle M Cummings
Do GLP-1RAs and SGLT-2is reduce cardiovascular events in black patients with type 2 diabetes? A systematic review and meta-analysis. Diabetes, obesity & metabolism 21 (10) (2019)
Carlos E Mendez, Rebekah J Walker, Christian R Eiler, Basem M Mishriky, Leonard E Egede
Insulin therapy in patients with type 2 diabetes and high insulin resistance is associated with increased risk of complications and mortality. Postgraduate medicine 131 (6) (2019)
Basem M Mishriky, Doyle M Cummings, Robert J Tanenberg, Walter J Pories
Re-examining insulin compared to non-insulin therapies for type 2 diabetes: when in the disease trajectory is insulin preferable? Postgraduate medicine 130 (8) (2018)